X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AANJANEYA LIFECARE with Elder Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. DATSONS LABS vs ELDER PHARMA - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. DATSONS LABS ELDER PHARMA DR. DATSONS LABS/
ELDER PHARMA
 
P/E (TTM) x -10.9 -0.2 - View Chart
P/BV x 0.2 0.1 160.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 DR. DATSONS LABS   ELDER PHARMA
EQUITY SHARE DATA
    DR. DATSONS LABS
Mar-14
ELDER PHARMA
Jun-14
DR. DATSONS LABS/
ELDER PHARMA
5-Yr Chart
Click to enlarge
High Rs126380 33.1%   
Low Rs31188 16.4%   
Sales per share (Unadj.) Rs133.0491.2 27.1%  
Earnings per share (Unadj.) Rs0.2-3.2 -4.8%  
Cash flow per share (Unadj.) Rs6.614.4 45.9%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs128.8376.5 34.2%  
Shares outstanding (eoy) m31.6620.54 154.1%   
Bonus/Rights/Conversions FCCB--  
Price / Sales ratio x0.60.6 101.8%   
Avg P/E ratio x516.1-89.3 -578.2%  
P/CF ratio (eoy) x11.819.7 60.1%  
Price / Book Value ratio x0.60.8 80.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m2,4775,833 42.5%   
No. of employees `000NANA-   
Total wages/salary Rs m562,179 2.6%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m4,21110,089 41.7%  
Other income Rs m79257 30.7%   
Total revenues Rs m4,28910,346 41.5%   
Gross profit Rs m569-792 -71.8%  
Depreciation Rs m204361 56.6%   
Interest Rs m4302,756 15.6%   
Profit before tax Rs m13-3,653 -0.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m-20-   
Extraordinary Inc (Exp) Rs m03,713 0.0%   
Tax Rs m6125 4.9%   
Profit after tax Rs m5-65 -7.3%  
Gross profit margin %13.5-7.8 -172.0%  
Effective tax rate %48.0-3.4 -1,402.0%   
Net profit margin %0.1-0.6 -17.6%  
BALANCE SHEET DATA
Current assets Rs m6,8529,240 74.2%   
Current liabilities Rs m6,7119,998 67.1%   
Net working cap to sales %3.3-7.5 -44.6%  
Current ratio x1.00.9 110.5%  
Inventory Days Days16146 347.3%  
Debtors Days Days31860 531.3%  
Net fixed assets Rs m3,67310,124 36.3%   
Share capital Rs m317206 153.9%   
"Free" reserves Rs m3,7615,582 67.4%   
Net worth Rs m4,0787,734 52.7%   
Long term debt Rs m1,6714,889 34.2%   
Total assets Rs m12,63322,882 55.2%  
Interest coverage x1.0-0.3 -316.5%   
Debt to equity ratio x0.40.6 64.8%  
Sales to assets ratio x0.30.4 75.6%   
Return on assets %3.411.8 29.3%  
Return on equity %0.1-0.8 -13.9%  
Return on capital %7.722.3 34.4%  
Exports to sales %22.93.0 753.4%   
Imports to sales %14.30.4 3,346.3%   
Exports (fob) Rs m964307 314.4%   
Imports (cif) Rs m60243 1,396.5%   
Fx inflow Rs m964307 314.4%   
Fx outflow Rs m607125 484.5%   
Net fx Rs m357181 196.9%   
CASH FLOW
From Operations Rs m1,34511,754 11.4%  
From Investments Rs m-2,256-561 402.4%  
From Financial Activity Rs m-1,200-6,762 17.7%  
Net Cashflow Rs m-2,1114,432 -47.6%  

Share Holding

Indian Promoters % 4.5 39.6 11.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 7.5 -  
FIIs % 1.4 16.8 8.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 94.1 36.1 260.7%  
Shareholders   20,807 16,479 126.3%  
Pledged promoter(s) holding % 0.0 77.6 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. DATSONS LABS With:   WYETH LTD  IPCA LABS  JUBILANT LIFE SCIENCES  SUN PHARMA  PIRAMAL ENTERPRISES  

Compare DR. DATSONS LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

Hindustan Aeronautics IPO: Yet Another Play on India's Defence Sector (IPO)

Mar 14, 2018

Should you apply for the IPO of state-run military aircraft maker Hindustan Aeronautics?

Bharat Dynamics IPO: Worth Betting on Defence Manufacturing? (IPO)

Mar 12, 2018

Should you apply for the IPO of Bharat Dynamics, India's first state-owned missile manufacturer?

Apollo Micro Systems Ltd. (IPO)

Jan 9, 2018

Should you subscribe to the IPO of Apollo Micro Systems Ltd?

Khadim India Ltd. (IPO)

Oct 31, 2017

Should you subscribe to the IPO of Khadim India Ltd?

Mahindra Logistics Ltd. (IPO)

Oct 28, 2017

Should you subscribe to the IPO of Mahindra Logistics Ltd?

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. DATSONS LABS SHARE PRICE


May 21, 2015 (Close)

TRACK DR. DATSONS LABS

  • Track your investment in DR. DATSONS LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DR. DATSONS LABS

DR. DATSONS LABS - ASTRAZENECA PHARMA COMPARISON

COMPARE DR. DATSONS LABS WITH

MARKET STATS